Like French health authorities, the Danish Health Authority is considering offering Danes who have received the first jab of the Astrazeneca vaccine another type of vaccine for their second vaccination, according to a Thursday press release coming from the Danish health authorities.
In the press statement, the Danish Health Authority notes that the second and final vaccination of people having received their first vaccination via the Astrazeneca vaccine will either contain the Astrazeneca vaccination type or a different one.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.